Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

European consortium for communicating gene- and cell-based therapy information.

Project description

DE EN ES FR IT PL

Reliable information concerning gene and cell therapy

Gene- and cell-based therapy is a promising method for many diseases like cancer, heart disease, diabetes and AIDS. The EU-funded EuroGCT project will develop reliable and accessible management of gene and cell therapy development information for European stakeholders. Specifically, it will provide patients, people affected by conditions, healthcare professionals and citizens with detailed scientific, legal, ethical and societal information, as well as with engagement opportunities to assist better-informed decision-making concerning gene and cell therapies. EuroGCT will also provide the research community and regulatory and healthcare authorities with information on the practical steps needed for gene and cell therapy development to support better decision-making at key points in new therapy development that would enable improved products.

Objective

The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) unites 49 partner organisations and institutions across Europe, including the major European advanced therapies learned societies, with the common goal of providing reliable and accessible information related to cell and gene therapy development to European stakeholders. EuroGCT has two major objectives:
• To provide patients, people affected by conditions, healthcare professionals and citizens with accurate scientific, legal, ethical and societal information and with engagement opportunities, and thus to support better informed decision-making related to cell and gene-based therapies.
• To facilitate better decision-making at key points in development of new therapies and thus enable improved product development, by providing the research community and regulatory and healthcare authorities with an information source on the practical steps needed for cell and gene therapy development.
To achieve our aims, EuroGCT will adopt a highly structured system for coordinated management of information related to cell and gene therapy development and, from this, will implement an ambitious programme of online and direct stakeholder information provision and engagement. All outputs will be delivered in 7 European languages, to ensure broad accessibility, and will be rigorously evaluated against measurable objectives throughout the project duration. The proposed consortium comprises leading cell and gene therapy-related organisations and basic and clinical research labs across Europe, including new member states; together with experts in product development, ethical, legal and societal issues, and in evaluating clinical outcomes; patient representatives; and science communicators. It thus is uniquely placed to develop a world-leading cell and gene therapy information resource and to meet the challenge outlined in Topic SC1-HCO-19-2020.

Fields of science

Not validated

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2020-Single-Stage-RTD

Funding Scheme

CSA - Coordination and support action

Coordinator

THE UNIVERSITY OF EDINBURGH
Net EU contribution
€ 1 710 483,75
Address
OLD COLLEGE, SOUTH BRIDGE
EH8 9YL Edinburgh
United Kingdom

See on map
Region
Scotland Eastern Scotland Edinburgh
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 710 483,75

Participants (46)

Share this page

Download

Last update: 18 November 2024

My Booklet

Permalink: https://cordis.europa.eu/project/id/965241

European Union, 2024